ALBUMIN AND AMINOLEBAN THERAPY IN CHRONIC LIVER CIRRHOSIS: DISTINCT AND COLLECTIVE INFLUENCES ON LIVER FUNCTION PARAMETERS

Abstract

This study examines the distinct and collective influences of Albumin and Aminoleban on liver function parameters in patients with Liver Cirrhosis. Chronic liver cirrhosis is associated with hypoalbuminemia, malnutrition, ascites, hepatic encephalopathy, and progressive impairment of liver function. Albumin therapy is commonly used to improve circulatory stability and reduce complications such as ascites and renal dysfunction, whereas Aminoleban therapy helps restore amino acid balance and improve nutritional and metabolic status. Previous studies support the effectiveness of both therapies. Long-term albumin therapy improved survival and reduced complications in decompensated cirrhosis patients, while Aminoleban improved serum albumin levels and nutritional status in cirrhotic patients with poor response to conventional therapy. This quantitative observational study was conducted at Allied Hospital I Faisalabad after obtaining official permission from the hospital administration. A total sample size of 40 chronic liver cirrhosis patients was selected through convenient sampling technique. Data were collected using structured data collection sheets including liver function parameters such as serum albumin, bilirubin, MELD-Na score, Child-Pugh score, ascites, and hepatic encephalopathy. The collected data were analyzed using Microsoft Excel and results were presented in tables and graphic forms for better interpretation. The findings of the study showed improvement in serum albumin levels, nutritional status, and liver function parameters among patients receiving albumin and Aminoleban therapy. Combination therapy demonstrated comparatively better outcomes in reducing complications and improving overall patient condition. The study concludes that both therapies play an important role in the comprehensive management of chronic liver cirrhosis patients.